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Recombinant outer membrane protein Q and putative lipoprotein from
Bordetella pertussis inducing strong humoral response were not protective alone in the
murine lung colonization model
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Abstract: Despite high vaccination coverage after introduction of whole cell (wP) and acellular pertussis (aP) vaccines, pertussis
resurgence has been reported in many countries. aP vaccines are commonly preferred due to side effects of wP vaccines and formulated
with aluminum hydroxide (Alum), which is not an effective adjuvant to eliminate Bordetella pertussis. Low efficiency of current aP
vaccines is thought to be the main reason for the resurgence for which newer generation aP vaccines are needed. In the present study,
immunogenicity and protective efficacy of outer membrane protein Q (OmpQ) and a putative lipoprotein (Lpp) from B. pertussis were
investigated in mice by using two different adjuvants, monophosphoryl lipid A (MPLA) or Alum. OmpQ and putative Lpp were cloned,
expressed, and purified from Escherichia coli. The proteins were formulated to immunize mice. Both recombinant OmpQ and putative
Lpp induced a significant increase in immunoglobulin G1 (IgG1) and immunoglobulin G2a (IgG2a) responses compared to the control
group. Moreover, MPLA-adjuvanted formulations resulted in higher IgG2a levels than Alum-adjuvanted ones. However, there were
no significant differences between test and control groups regarding interferon-gamma (IFN-γ) levels, and the mice lung colonization
experiments indicated that neither rOmpQ nor rLpp could confer protection alone against B. pertussis challenge.
Key words: Adjuvants, Bordetella pertussis, pertussis vaccines, recombinant proteins

1. Introduction
Pertussis (whooping cough) is a highly contagious
respiratory tract infection, the causative agent of which
is a gram-negative, nonspore-forming, and encapsulated
coccobacillus called Bordetella pertussis (Finger and von
Koenig, 1996). The disease is common among infants
and children, but increased incidence rate in older ages
has also been reported, suggesting that adolescents and
adults can serve as a reservoir to spread the pathogen to
infants who are too young for vaccination but suffer from
severe complications including death in rare cases (Mooi et
al., 2007; Hewlett et al., 2014; Sealey et al., 2016). Despite
high vaccination coverage (86% in 2015), 142,512 global
pertussis cases were reported in 2015 and it is still an
important public health problem due to pertussis outbreaks
(Burns et al., 2014; WHO, 2017).
Whole cell pertussis (wP) vaccines combined with
tetanus and diphtheria toxoids (DTwP) confer protection
mainly through CD4+ T helper (Th) 1 cells, Th17 cells,
interferon gamma (IFN-γ), and tumor necrosis factor
(TNF-α), all of which provide effective clearance of B.
* Correspondence: ozcengiz@metu.edu.tr

pertussis (Edwards, 2014; Edwards and Berbers, 2014).
Although the protective capacity of DTwP is quite efficient,
it has already been replaced with acellular pertussis (DTaP)
vaccines due to safety concerns (Warfel and Edwards,
2015). Several DTaP vaccines have been produced with
2 to 5 virulence factors of B. pertussis including pertussis
toxins (PT), pertactin (PRN), fimbriae (Fim 2 and 3), and
filamentous hemagglutinin (FHA) (Edwards et al., 1995).
Variations due to polymorphisms have been reported
in some virulence factors found in aP vaccines, possibly
resulting in differences in antibody efficiencies and
immunological memory against the disease (Mooi et al.,
1998, 2009; King et al., 2001; Lam et al., 2012). Comparative
whole-genome sequence analyses of dozens of B. pertussis
strains from Finland, China, and the Netherlands indicated
that evolution in this pathogen has been a major driving
force (Xu et al., 2015). Thus, as already emphasized (Tefon
et al., 2013), discovery of new protective antigens has been
a widely accepted strategy in recent years.
It is well known that the Th1-type response, which
mediates cellular immunity, is required for bacterial
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clearance in pertussis infection in addition to the Th2
response, which mainly induces antibody production
from B cells. In particular, IFN-γ produced by Th1 cells
is an essential element having a role in the prevention of
bacterial spread (Fedel et al., 2015). Besides the antigen
itself, adjuvants also play an important role in stimulation
of the immune response against antigens. Current DTaP
vaccines are adjuvanted with aluminum hydroxide
(Alum), which predominantly helps to induce Th2type immunity that is not as effective as Th1 response in
clearance of B. pertussis (Edwards and Berbers, 2014).
Therefore, substituting Alum with new adjuvants such as
a TLR agonist is required to enhance protective immunity
(Ross et al., 2013).
In immunoproteomic studies on B. pertussis conducted
in our laboratory (Altındiş et al., 2009; Tefon et al., 2011),
outer membrane protein Q (OmpQ) and a putative
lipoprotein (Lpp), BP2919, were among immunogenic
surface proteins of the pathogen. Subsequent metareverse
vaccinology analysis of our data (Emrah Altındiş, personal
communication) in pangenomic databases suggested the
potential utility of these proteins as vaccine component
candidates, prioritizing them for experimental testing.
Protective immunogenicity of outer membrane proteins
and lipoproteins has been demonstrated in several
microorganisms including Pseudomonas aeruginosa,
Neisseria meningitidis, Pasteurella multocida, and
Escherichia coli (Mansouri et al., 1999; Fletcher et al., 2004;
Wu et al., 2007; Okay et al., 2012; Guan et al., 2015). The
present study aims to investigate immune responses to
recombinant OmpQ and putative Lpp from B. pertussis
and their protectivity in a mouse model by using Alumand monophosphoryl lipid A (MPLA)-adjuvanted
formulations of these proteins.
2. Materials and methods
2.1. Bacterial strains and vectors
B. pertussis Tohama I, a vaccine strain, and Saadet, a
local strain in Turkey, were used in the study. Cloning
and expression studies were carried out in E. coli DH5α
(ATCC) and E. coli BL21 (DE3) (Novagen, Germany),
respectively. While pGEMT Easy (Promega, USA) was
used for PCR cloning, expression of recombinant proteins
was performed with the pET28a (+) vector (Novagen,
Germany).
2.2. Cloning of ompQ and BP2919
The ompQ and BP2919 genes were amplified from B.
pertussis Tohama I genomic DNA through PCR with
specifically designed primers including BamHI and
BglII restriction sites. The primers of ompQ were as
follows: forward primer 5’ - ggatccatgcgtcgtcttctcgtc - 3’
and reverse primer 5’ - agatcttcagaagcgctgggtcattcc - 3’.
The primers of BP2919 were as follows: forward primer
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5’ - ggatccgtgccccgaatcgcg - 3’ and reverse primer 5’ agatcttcagcggcggggcaag - 3’. After PCR, the products were
cloned into pGEM®-T Easy in E. coli DH5α. The expression
vector pET-28a (+) was digested with BamHI and the
genes were then cloned into pET-28a (+) in E. coli BL21
(DE3) (pET28-OmpQ and pET28-Lpp). Ligation reactions
contained 500 ng of DNA samples, 2 µL of vector, 1 µL
of 10X ligation buffer, 1 µL of T4 ligase, and sterile dH2O
to complete the volume. The mixtures were incubated at
4 °C for 16 h. Verification of the cloned DNA sequences
was carried out at RefGen Inc. using the chain termination
method (Ankara, Turkey) and the BLAST search of the
NCBI website was used to compare the deduced nucleotide
sequences.
2.3. Expression of recombinant OmpQ and putative Lpp
Ligation product (10 µL) was mixed with 100 µL of
competent E. coli BL21 cells. After incubation on ice for 20
min, a heat shock was applied at 42 °C for ~70 s. Then the
mixture was incubated on ice for 5 min. After addition of
900 µL of Luria broth (LB; Merck, Germany) and incubation
for 80 min at 37 °C, the pellets were obtained through
centrifugation. The pellets were dissolved in LB and the
cells were inoculated onto LB agar plates supplemented
with 30 µg/m: kanamycin (Sigma, Germany).
Stocks of E. coli BL21 (DE3) cells at –80 °C transformed
with pET28-OmpQ or pET28-Lpp were inoculated on
LB agar plates containing 30 µg/mL kanamycin. After
overnight incubation, a single colony was selected to be
inoculated on 10 mL of LB supplemented with kanamycin.
After incubation with shaking for 16–18 h, 3 mL of seed
culture was added into two volumes of 150 mL of fresh
LB containing kanamycin. The cultures were incubated
at 37 °C at 200 rpm until OD600 was around 0.6. One
culture remained as an uninduced control and the other
was induced by isopropyl β-D-1-thiogalactopyranoside
(IPTG; Sigma, Germany) at a final concentration of 1 mM
for production of the recombinant proteins. After 5 h of
induction, the cells were harvested and resuspended in
denaturing solubilization buffer (DSB; 1 M NaCl, 50 mM
NaH2PO4, and 8 M urea, pH 8.0). After 2 cycles of freezethaw, the samples were lysed through sonication using a
CP70T Ultrasonic Processor (Cole-Parmer, USA) on ice.
They were then centrifuged and the supernatants were
collected to purify the recombinant proteins.
2.4. Purification of recombinant OmpQ and putative Lpp
Protino Ni-TED 2000 packed columns (Macherey-Nagel,
Germany) were used for the purification process. After
equilibration with 4 mL of DSB, the supernatants were
passed through columns containing nickel ions that
the polyhistidine parts of tagged proteins can bind. The
columns were rinsed with DSB three times and then the
recombinant proteins were eluted with 3 mL of denaturing
elution buffer (DEB; 8 M urea, 50 mM NaH2PO4, 1 M
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NaCl, and 250 mM imidazole, pH 8.0). Dialysis of the
solutions containing eluted proteins was performed in
dialysis buffer (50 mM NaH2PO4, 500 mM NaCl, and
4 M urea, pH 8.0). After filter sterilization with 0.2 µm
filters, concentrations of recombinant OmpQ (rOmpQ)
and recombinant putative Lpp (rLpp) were evaluated by
Bradford assay as described by Ramagli and Rodriguez
(1985).
2.5. SDS-PAGE and western blotting
To visualize the purified proteins, 12% acrylamide/bisacrylamide gels were prepared with a Bio-Rad cell system
(Bio-Rad, USA). The gels were stained with colloidal
Coomassie blue. Immunogenicity of the recombinant
proteins was confirmed through western blotting as
described by Altındiş et al. (2009). The antisera against
B. pertussis Tohama I used in western blot analyses were
obtained as previously described (Tefon et al., 2011).
2.6. Vaccine formulations and mice immunization
rOmpQ or rLpp at 40 µg/mL was mixed with Alum
(InvivoGen, USA) or MPLA (InvivoGen, USA) for mice
immunization experiments. Fifteen BALB/c female
mice weighing between 16 and 18 g were used for each
group and intraperitoneally immunized with 40 µg/
mL rOmpQ-Alum, rOmpQ-MPLA, rLpp-Alum, rLppMPLA, or phosphate-buffered saline (PBS) solution as
negative control. The injections were performed at day
0 and day 21. All animal experiments were performed
under the approval of the Ethics Committee on Animal
Experimentation, Middle East Technical University,
Ankara, Turkey (METU Etik-2015/10).
2.7. Measurement of antibody levels
Sera were obtained from the tail veins of mice after
the first and second immunizations (day 20 and day
30, respectively). Test sera were then used to measure
specific immunoglobulin (Ig) G types: IgG1 and IgG2a.
rOmpQ or rLpp at 4 µg/well in carbonate/bicarbonate
(0.05 M, pH 9.6) buffer was used to coat each well of
96-well microplates. After incubation at 4 °C overnight,
the microplates were washed three times with washing
solution (1X PBS, 1% Tween 20). Blocking solution (4%
BSA, 5% sucrose in PBS) was added to each well and
incubated at 37 °C for 1 h. Murine sera diluted from 1:100
to 1:102,400 were added to the wells and the microplates
were incubated at 37 °C for 1 h. After washing three times,
alkaline phosphatase conjugated rat antimouse IgG1
or IgG2a (Southern Biotech, UK) diluted in blocking
solution was added to each well and the microplates were
incubated at 37 °C for 1 h. After washing, p-nitrophenyl
phosphate disodium salt (Thermo Scientific, USA) was
used to develop color detectable at 405 nm. Antibody
titers were calculated as the reciprocal of the last dilution
that gave a signal.

2.8. Determination of interferon-gamma (IFN-γ) levels
The spleens of three immunized mice from each group
were excised at day 30 (before bacterial challenge) and
resuspended in RPMI 1640 medium containing 10%
FBS (Biochrom, UK) and 1% penicillin/streptomycin
(Biochrom, UK). After homogenization, splenocytes were
diluted at a concentration of 1 × 106 cells/well and placed
into each well of a 96-well microplate. After incubation in
a CO2 incubator for 1 h at 37 °C, the cells were induced
with PBS as a negative control, concanavalin A (ConA)
(Sigma, USA) as a positive control, or 30 mg/mL rOmpQ
or rLpp. After 3 days, the supernatants were collected
and IFN-γ level was evaluated with a mouse IFN-γ
ELISA development kit (Mabtech, USA) according to the
manufacturer’s protocol.
2.9. Bacterial challenge of mice
Immunized mice were intranasally challenged at day
31 with the live B. pertussis Saadet strain, which is more
virulent than Tohama I. A suspension of 50 µL containing
2.5 × 109 CFU was administered to each nostril of the mice.
2.10. Evaluation of bacterial colonization in mice lungs
The lungs of four immunized mice from each group were
removed at day 5, 8, and 14, respectively, after bacterial
challenge. They were homogenized and diluted in 0.85%
saline solution supplemented with 1% casamino acid.
Serially diluted samples were inoculated into Cohen–
Wheeler agar plates containing cephalexin (40 mg/L) and
incubated at 37 °C for 3 to 4 days. The log10 weighted mean
numbers of CFU/lung were calculated for each day.
2.11. Statistical analysis
The results were represented as means and standard
deviations and they were analyzed through ANOVA along
with Tukey’s test for comparison of datasets.
3. Results
3.1. Expression and purification of the recombinant
proteins
After amplification of the genes and cloning into the pET28a (+) expression vector, pET28-OmpQ and pET28Lpp were transformed into E. coli BL21 (DE3) and Histagged recombinant proteins were expressed upon IPTG
induction. The recombinant proteins (OmpQ, ~39 kDa;
Lpp, ~25.5 kDa) were purified and analyzed by SDS-PAGE
after staining with Coomassie blue (Figures 1A and 1B).
3.2. Western blot assays of the recombinant proteins
Immunogenicity of purified rOmpQ and rLpp was analyzed
through western blotting by using sera collected from
mice subcutaneously immunized with heat-inactivated B.
pertussis Tohama I. The blots verified the immunogenicity
of the recombinant proteins (Figures 2A and 2B). The ca.
60 kDa band seen in uninduced cell lysate most probably
corresponds to Hsp60 (GroEL) of E. coli. It is known that
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Figure 1. SDS-PAGE of recombinant OmpQ and Lpp. A) Lane 1: Uninduced cell lysate, lanes 2 and 3: isopropyl β-D-1thiogalactopyranoside (IPTG)-induced cell lysate, lane 4: purified recombinant OmpQ (~39 kDa), M: Precision Plus Protein Unstained
Standards, #161-0363. B) Lane 1: Uninduced cell lysate, lanes 2 and 3: IPTG-induced cell lysate, lane 4: purified recombinant Lpp (~25.5
kDa), M: Pageruler Plus Prestained Protein Ladder, #SM1811.
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Figure 2. Western blot analyses with antisera against Bordetella pertussis Tohama I. A) Lane 1: Uninduced cell lysate, lane 2: purified
recombinant OmpQ. B) Lane 1: Uninduced cell lysate, Lane 2: purified recombinant Lpp. M: Pageruler Plus Prestained Protein Ladder,
#SM1811.
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high sequence similarities are present in Hsp60 proteins
among species (Maleki et al., 2016) and cross-reactivity
can be observed (Hinode et al., 1998).
3.3. Humoral responses against the recombinant proteins
IgG1 and IgG2a levels were detected via ELISA using the
sera from mice immunized with rOmpQ-Alum, rOmpQMPLA, rLpp-Alum, rLpp-MPLA, and PBS. Both rOmpQ
and rLpp adjuvanted with Alum or MPLA demonstrated
strong IgG1 and IgG2a responses, especially after the
second vaccinations, when compared to the control groups
(Figures 3A and 3B). Moreover, IgG2a levels were clearly
higher in MPLA-adjuvanted formulations than Alumadjuvanted ones.
3.4. Antigen-specific interferon-gamma levels
Splenocyte culture was obtained from the spleens of
immunized mice and antigen-specific IFN-γ level was
evaluated. The measurement of IFN-γ levels demonstrated
that there were no significant differences between negative
controls and mice immunized with rOmpQ or rLpp,
although a slight but not significant increase was observed
in MPLA-adjuvanted formulations (Figure 4).
3.5. Bacterial colonization in the lungs of mice
The lungs of immunized and challenged mice were used
to assess bacterial colonization. The results revealed
that neither rOmpQ nor rLpp adjuvanted with Alum or
MPLA alone induced a significant decrease in bacterial
colonization, although immunization with MPLAadjuvanted rOmpQ resulted in a slight but not significant
decrease at day 14 (Figure 5).
4. Discussion
Pertussis is still a public health problem due to pertussis
outbreaks in 3- or 4-year cycles although it is a vaccinepreventable disease. In 2015, 142,512 pertussis cases

4.5
4
3.5
3
2.5
2
1.5
1
0.5
0

*

1st vac.

IgG2a
*

*

*

*
*

2nd vac.
PBS

IgG1

1st vac.

rOmpQ-Alum

*

2nd vac.
rOmpQ-MPLA

Antibody titer (log10)

Antibody titer (log10)

IgG1

were globally reported even in the presence of a high
vaccination rate (86%) (WHO, 2017). In addition to
DTwP and DTaP, Tdap vaccines have been developed
for adolescents and adults due to pertussis incidence
among older ages (Tefon et al., 2013; Sealey et al., 2016).
Despite the presence of vaccines and high vaccination
coverage, pertussis outbreaks have been observed in
many countries including the United Kingdom, the
United States, Australia, and the Netherlands (Burns
et al., 2014). The disease killed 10 babies in 2010 and
a pertussis epidemic was declared with 9935 cases in
2014 in California, USA (CDC, 2014). In 2012, 10,000
pertussis cases were confirmed in the United Kingdom
and 14 infants died. In the same year, Minnesota, USA,
also experienced a large pertussis epidemic where 4144
pertussis cases were reported (Sealey et al., 2015). It is
suggested that many factors contribute to the resurgence
of pertussis including increased awareness and improved
diagnosis, antigenic variations in circulating isolates,
lower efficiency of current aP vaccines, and early waning
immunity (Chiappini et al., 2015). Moreover, aP vaccines
are adjuvanted with Alum, which is well known to mainly
help to induce Th2-type immune response instead of Th1.
Th2 response alone is not sufficient to completely eliminate
B. pertussis that can survive intracellularly; Th1 response
is also required in pertussis infection due to its ability to
mediate activation of neutrophils and macrophages as
well as formation of opsonizing antibodies such as IgG2a
(McKee et al., 2007; Allen and Mills, 2014; Edwards and
Berbers, 2014). While IgG1 has a role in the neutralization
of toxins and prevention of bacterial adherence in the
respiratory tract (Barnard et al., 1996), IFN-γ secreted by
Th1 cells plays a key role in clearance of B. pertussis by
enhancing phagocytosis and complement fixation (Higgs
et al., 2012).
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Figure 3. Antibody responses to recombinant OmpQ (rOmpQ) and Lpp (rLpp) formulated with Alum (aluminum hydroxide) or MPLA
(monophosphoryl Lipid A). A) IgG1 and IgG2a responses to recombinant OmpQ-Alum and OmpQ-MPLA after first and second
immunizations. B) IgG1 and IgG2a responses to recombinant Lpp-Alum and Lpp-MPLA after first and second immunizations. Control
mice immunized with PBS were used as negative control. The results are represented as mean ± SD (** P < 0.05).
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Figure 4. IFN-γ production by spleen cells of mice immunized with recombinant OmpQ
(rOmpQ) or Lpp (rLpp) formulated with Alum (Aluminum hydroxide) or MPLA
(monophosphoryl lipid A). Spleen cells induced with PBS and ConA were used as negative
and positive controls, respectively. The results are represented as mean ± SD (** P < 0.01).
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Figure 5. Mean numbers of CFU/mL per lung of groups of mice
intraperitoneally immunized with recombinant OmpQ (rOmpQ)
or Lpp (rLpp) formulated with Alum (aluminum hydroxide) or
MPLA (monophosphoryl lipid A). Control mice immunized
with PBS were used as negative control. The results are presented
as mean CFU/mL per lung ± SD.

Studies have mainly been focused on improving current
aP vaccines by taking two common approaches into
consideration: discovery of novel vaccine antigens from
B. pertussis and development of new vaccine formulations
with more effective adjuvants. In an immunoproteomic
analysis, Hayes et al. (2011) identified differentially
expressed proteins under iron starvation. Some of the
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identified proteins were immunogenic and one protein
called IRP1-3 strongly reacted with IgG purified from
infected individuals. Moreover, it induced strong IgG1 and
IgG2a production along with high IFN-γ and IL-10 levels
in mice. The authors also demonstrated the protective
capacity of another novel antigen from B. pertussis called
AfuA, which is an iron-binding protein (Hayes et al.,
2013). A proteomic analysis of B. pertussis biofilm content
revealed 11 abundant proteins (de Gouw et al., 2014).
When the protective activity of the most abundant protein,
BipA, was investigated in mice, opsonization of the
pathogen along with a decrease in bacterial colonization in
the lungs was recorded. In another study, a novel antigen,
iron superoxide dismutase (FeSOD), previously identified
by our immunoproteomic studies, was evaluated in terms
of immune response and protectivity in mouse models
(Yılmaz et al., 2016). It was demonstrated that rFeSOD,
especially when adjuvanted with MPLA, induced strong
IgG1 and IgG2a production and stimulated production of
high levels of IFN-γ along with a significant reduction in
bacterial colonization in the lungs of immunized mice. As
to the use of new adjuvant systems in aP vaccines rather
than Alum, TLR4 ligands such as MPLA can be promising
adjuvants because of their capacity to induce activation of
Th1 cells, resulting in IFN-γ production and B. pertussis
clearance (Ross et al., 2013; Fedel et al., 2015).
In the present study, immunizations with rOmpQ
or rLpp adjuvanted with Alum or MPLA resulted in a
significant increase in IgG1 and IgG2a levels as compared
to the control groups. Furthermore, the levels of IgG2a
were higher in MPLA-adjuvanted formulations than Alum
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ones, suggesting the potential of MPLA as an effective
adjuvant for aP vaccines. Although immunization
with MPLA-adjuvanted formulations resulted only
in a slight and insignificant increase in IFN-γ level, it
is known that even a low level of IFN-γ is sufficient to
induce class switching to IgG2a (Finkelman et al., 1988),
which may explain high IgG2a titers obtained with these
formulations. In protection studies related to B. pertussis
infection, determination of bacterial colonization in the
lungs of mice is an effective way to elucidate protective
immunity against the pathogen because of the presence
of a direct correlation between them (Hayes et al.,
2011, 2013). In our study, no significant decrease in
bacterial colonization was observed in the lungs of mice
immunized with rOmpQ or rLpp adjuvanted with Alum
or MPLA, although a slight decrease was present at day
14 in rOmpQ-MPLA immunization. The lack of decrease
in bacterial colonization might be related to the low level
of IFN-γ as it is crucial for elimination of B. pertussis
from the lungs. There are examples in the literature of
proteins that were found to be highly immunogenic
but could not confer protection against the relevant
infection, such as P55 of Borrelia burgdorferi, gpA of
Pneumocystis carinii, and human metapneumovirus G
protein (Feng et al., 1996; Gigliotti et al., 1998; Ryder et
al., 2010). Moreover, in one study, while the vaccination
of mice with recombinant autotransporter protein
BrkA of B. pertussis as the only B. pertussis antigen

did not protect against colonization by B. pertussis, it
significantly increased the efficacy of the two-pertussiscomponent DTaP vaccine (PT, FHA) against B. pertussis
in a sublethal intranasal murine respiratory challenge
model (Marr et al., 2008). Its inclusion led to an antigen
combination that was as efficacious in protecting mice
as the commercial Infranrix vaccine that also contains
PT and FHA but PRN instead of rBrkA. The authors
suggested that BrkA is a promising candidate antigen
to improve existing aP vaccines for use in humans.
Although we did not test the protective efficacy of
rOmpQ and/or rLpp when combined in two- or morepertussis-component DTaP vaccines, our findings do
not exclude the protective effectiveness of these proteins
since the high amounts of IgG2a antibodies (high IgG2a/
IgG1 ratio) induced by rOmpQ-MPLA and rLpp-MPLA
are likely indicative of the existence of the Th1 type of
immune response. Regarding the dominant effect of PT
in aP vaccines (Xing et al., 2014), future experimental
studies on new candidate components in mice models
should investigate if they cause a significant contribution
to the protectivity of the PT component rather than any
substitutional effect of them on the other immunogenic
proteins contained in commercial vaccines.
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